SCHEDULE: Cormorant Asset Management Discloses Quince Therapeutics Stake

Cormorant Asset Management, LP and Bihua Chen have reported a 9.99% beneficial ownership in Quince Therapeutics, Inc., primarily through convertible securities.

Summary

• Cormorant Asset Management, LP and Bihua Chen have jointly filed a Schedule 13G, reporting beneficial ownership of 108,029 shares of Quince Therapeutics, Inc. common stock.
• This ownership represents 9.99% of the class of securities.
• The reported shares are primarily issuable upon conversion/exercise of various convertible securities and warrants, subject to a 9.99% beneficial ownership limitation.
• Without this limitation, the reporting persons would beneficially own more than 9.99% of the outstanding common stock.
• The filing is made as of June 30, 2026, with the certification dated August 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but capped ownership stake by an investment manager, which is typical for institutional investors managing risk.

Positives

• Significant institutional investor interest in Quince Therapeutics, Inc., as evidenced by the 9.99% stake.
• The ownership is structured through convertible securities, suggesting a strategic investment approach.

Negatives

• The beneficial ownership is capped at 9.99% due to exercise limitations on convertible securities, preventing a larger stake.
• The filing does not provide details on the specific terms or performance of the convertible securities.

Risks

• Potential for future dilution if the convertible securities are exercised and more shares are issued.
• The 9.99% ownership cap may limit the reporting persons' ability to influence company decisions beyond that threshold.
• The value of the investment is tied to the performance of Quince Therapeutics, Inc. and the market for its common stock.

Future Outlook

The filing does not contain forward-looking statements or specific future guidance from the company. The outlook is implicitly tied to the potential exercise of convertible securities and the company's stock performance.

Management Comments

• The filing should not be construed as an admission that any reporting person is the beneficial owner of the shares reported herein for the purposes of Section 13 of the Act.
• The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported herein.
• Cormorant Global Healthcare Master Fund, LP and Cormorant Private Healthcare Fund VI, LP have the right to receive or the power to direct the receipt of dividends or proceeds from the sale of more than 5% of the shares.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by investment managers like Cormorant Asset Management are common for significant stakes in publicly traded companies, especially in the biotechnology and healthcare sectors where Quince Therapeutics operates. The 9.99% threshold is a standard reporting requirement and often a strategic limit for institutional investors.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, but the capped ownership and reliance on convertible securities might temper enthusiasm.
• Creditors: The filing does not directly impact creditors, but the company's financial health, which influences debt repayment, is indirectly relevant.
• Management: May need to consider the influence of a significant, albeit capped, institutional holder.

Next Steps

• Continued monitoring of Quince Therapeutics, Inc. by Cormorant Asset Management, LP and Bihua Chen.
• Potential exercise of convertible securities and warrants, subject to the 9.99% ownership limitation.

Key Dates

Keywords

Quince Therapeutics, Schedule 13G, Cormorant Asset Management, Beneficial Ownership, Convertible Securities, Warrants, Institutional Investor